Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in Solid Organ Transplant Patients
Varicella zoster virus (VZV) and the two herpes simplex viruses (HSV) are human α‐herpesviruses that establish life‐long latency in neural ganglia after initial primary infection. In the solid organ transplant (SOT) population, manifestations of VZV or HSV may be seen in up to 70% of recipients if n...
Gespeichert in:
| Veröffentlicht in: | American journal of transplantation 2013-02, Vol.13 (s3), p.55-66 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 66 |
|---|---|
| container_issue | s3 |
| container_start_page | 55 |
| container_title | American journal of transplantation |
| container_volume | 13 |
| creator | Zuckerman, R. A. Limaye, A. P. |
| description | Varicella zoster virus (VZV) and the two herpes simplex viruses (HSV) are human α‐herpesviruses that establish life‐long latency in neural ganglia after initial primary infection. In the solid organ transplant (SOT) population, manifestations of VZV or HSV may be seen in up to 70% of recipients if no prophylaxis is used, some of them life and organ threatening. While there are effective vaccines to prevent VZV primary infection and reactivation in immunocompetent adults, these vaccines are contraindicated after SOT because they are live‐virus vaccines. For HSV, prevention has focused primarily on antiviral strategies because the immunologic correlates of protection and control are different from VZV, making vaccine development more challenging. Current antiviral therapy remains effective for the majority of clinical VZV and HSV infections. |
| doi_str_mv | 10.1111/ajt.12003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1323807217</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2873744821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4523-e0738d6c4e31cc39535decb9bba3b14304bd812d4cd0a65f98d1ebeec454fb103</originalsourceid><addsrcrecordid>eNqFkU9LAzEQxYMoVqsHv4AEvOihbZLJ_ulRRK1SUGjtwYNLdjMrKdvdNdlF_fbGru1BEOcyA-83Dx6PkBPOhtzPSC2bIReMwQ454CFjg5BL2N3eEPTIoXNLxngkYrFPegJARoLLA_KyUNZkWBSKPleuQUsXxraOni-eFxdUlZpO0Nbo6Mys6gI_NvJk5mVT0llVGE0f7Ksq6dyq0tWFKhv6qBqDZeOOyF6uCofHP7tPnm6u51eTwfTh9u7qcjrIZCBggCyCWIeZROBZBuMAAo1ZOk5TBanPwmSqYy60zDRTYZCPY80xRfTfMk85gz4573xrW7216JpkZdw6VolV6xIOAmLmI0f_oyKGSARjKTx69gtdVq0tfRBPRQJkCCF46qKjMls5ZzFPamtWyn4mnCXf_SS-n2Tdj2dPfxzbdIV6S24K8cCoA95NgZ9_OyWX9_PO8gvLHpcN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1272346363</pqid></control><display><type>article</type><title>Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in Solid Organ Transplant Patients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Zuckerman, R. A. ; Limaye, A. P.</creator><creatorcontrib>Zuckerman, R. A. ; Limaye, A. P.</creatorcontrib><description>Varicella zoster virus (VZV) and the two herpes simplex viruses (HSV) are human α‐herpesviruses that establish life‐long latency in neural ganglia after initial primary infection. In the solid organ transplant (SOT) population, manifestations of VZV or HSV may be seen in up to 70% of recipients if no prophylaxis is used, some of them life and organ threatening. While there are effective vaccines to prevent VZV primary infection and reactivation in immunocompetent adults, these vaccines are contraindicated after SOT because they are live‐virus vaccines. For HSV, prevention has focused primarily on antiviral strategies because the immunologic correlates of protection and control are different from VZV, making vaccine development more challenging. Current antiviral therapy remains effective for the majority of clinical VZV and HSV infections.</description><identifier>ISSN: 1600-6135</identifier><identifier>EISSN: 1600-6143</identifier><identifier>DOI: 10.1111/ajt.12003</identifier><identifier>PMID: 23347214</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Adult ; Antiviral Agents - therapeutic use ; Chickenpox - complications ; Chickenpox - etiology ; Child ; Drug Resistance, Viral ; Ganglia - metabolism ; Herpes simplex ; Herpes Simplex - complications ; Herpes Simplex - etiology ; Herpes simplex virus ; Herpesviridae ; Herpesvirus 3, Human - metabolism ; Humans ; Organ Transplantation - adverse effects ; prevention ; Risk Factors ; Simplexvirus - metabolism ; transplantation ; treatment ; Treatment Outcome ; Vaccines ; varicella ; Varicella-zoster virus</subject><ispartof>American journal of transplantation, 2013-02, Vol.13 (s3), p.55-66</ispartof><rights>Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons</rights><rights>Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.</rights><rights>2013 American Society of Transplantation and the American Society of Transplant Surgeons</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4523-e0738d6c4e31cc39535decb9bba3b14304bd812d4cd0a65f98d1ebeec454fb103</citedby><cites>FETCH-LOGICAL-c4523-e0738d6c4e31cc39535decb9bba3b14304bd812d4cd0a65f98d1ebeec454fb103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajt.12003$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajt.12003$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23347214$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zuckerman, R. A.</creatorcontrib><creatorcontrib>Limaye, A. P.</creatorcontrib><title>Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in Solid Organ Transplant Patients</title><title>American journal of transplantation</title><addtitle>Am J Transplant</addtitle><description>Varicella zoster virus (VZV) and the two herpes simplex viruses (HSV) are human α‐herpesviruses that establish life‐long latency in neural ganglia after initial primary infection. In the solid organ transplant (SOT) population, manifestations of VZV or HSV may be seen in up to 70% of recipients if no prophylaxis is used, some of them life and organ threatening. While there are effective vaccines to prevent VZV primary infection and reactivation in immunocompetent adults, these vaccines are contraindicated after SOT because they are live‐virus vaccines. For HSV, prevention has focused primarily on antiviral strategies because the immunologic correlates of protection and control are different from VZV, making vaccine development more challenging. Current antiviral therapy remains effective for the majority of clinical VZV and HSV infections.</description><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Chickenpox - complications</subject><subject>Chickenpox - etiology</subject><subject>Child</subject><subject>Drug Resistance, Viral</subject><subject>Ganglia - metabolism</subject><subject>Herpes simplex</subject><subject>Herpes Simplex - complications</subject><subject>Herpes Simplex - etiology</subject><subject>Herpes simplex virus</subject><subject>Herpesviridae</subject><subject>Herpesvirus 3, Human - metabolism</subject><subject>Humans</subject><subject>Organ Transplantation - adverse effects</subject><subject>prevention</subject><subject>Risk Factors</subject><subject>Simplexvirus - metabolism</subject><subject>transplantation</subject><subject>treatment</subject><subject>Treatment Outcome</subject><subject>Vaccines</subject><subject>varicella</subject><subject>Varicella-zoster virus</subject><issn>1600-6135</issn><issn>1600-6143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9LAzEQxYMoVqsHv4AEvOihbZLJ_ulRRK1SUGjtwYNLdjMrKdvdNdlF_fbGru1BEOcyA-83Dx6PkBPOhtzPSC2bIReMwQ454CFjg5BL2N3eEPTIoXNLxngkYrFPegJARoLLA_KyUNZkWBSKPleuQUsXxraOni-eFxdUlZpO0Nbo6Mys6gI_NvJk5mVT0llVGE0f7Ksq6dyq0tWFKhv6qBqDZeOOyF6uCofHP7tPnm6u51eTwfTh9u7qcjrIZCBggCyCWIeZROBZBuMAAo1ZOk5TBanPwmSqYy60zDRTYZCPY80xRfTfMk85gz4573xrW7216JpkZdw6VolV6xIOAmLmI0f_oyKGSARjKTx69gtdVq0tfRBPRQJkCCF46qKjMls5ZzFPamtWyn4mnCXf_SS-n2Tdj2dPfxzbdIV6S24K8cCoA95NgZ9_OyWX9_PO8gvLHpcN</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>Zuckerman, R. A.</creator><creator>Limaye, A. P.</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201302</creationdate><title>Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in Solid Organ Transplant Patients</title><author>Zuckerman, R. A. ; Limaye, A. P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4523-e0738d6c4e31cc39535decb9bba3b14304bd812d4cd0a65f98d1ebeec454fb103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Chickenpox - complications</topic><topic>Chickenpox - etiology</topic><topic>Child</topic><topic>Drug Resistance, Viral</topic><topic>Ganglia - metabolism</topic><topic>Herpes simplex</topic><topic>Herpes Simplex - complications</topic><topic>Herpes Simplex - etiology</topic><topic>Herpes simplex virus</topic><topic>Herpesviridae</topic><topic>Herpesvirus 3, Human - metabolism</topic><topic>Humans</topic><topic>Organ Transplantation - adverse effects</topic><topic>prevention</topic><topic>Risk Factors</topic><topic>Simplexvirus - metabolism</topic><topic>transplantation</topic><topic>treatment</topic><topic>Treatment Outcome</topic><topic>Vaccines</topic><topic>varicella</topic><topic>Varicella-zoster virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zuckerman, R. A.</creatorcontrib><creatorcontrib>Limaye, A. P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zuckerman, R. A.</au><au>Limaye, A. P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in Solid Organ Transplant Patients</atitle><jtitle>American journal of transplantation</jtitle><addtitle>Am J Transplant</addtitle><date>2013-02</date><risdate>2013</risdate><volume>13</volume><issue>s3</issue><spage>55</spage><epage>66</epage><pages>55-66</pages><issn>1600-6135</issn><eissn>1600-6143</eissn><abstract>Varicella zoster virus (VZV) and the two herpes simplex viruses (HSV) are human α‐herpesviruses that establish life‐long latency in neural ganglia after initial primary infection. In the solid organ transplant (SOT) population, manifestations of VZV or HSV may be seen in up to 70% of recipients if no prophylaxis is used, some of them life and organ threatening. While there are effective vaccines to prevent VZV primary infection and reactivation in immunocompetent adults, these vaccines are contraindicated after SOT because they are live‐virus vaccines. For HSV, prevention has focused primarily on antiviral strategies because the immunologic correlates of protection and control are different from VZV, making vaccine development more challenging. Current antiviral therapy remains effective for the majority of clinical VZV and HSV infections.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>23347214</pmid><doi>10.1111/ajt.12003</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1600-6135 |
| ispartof | American journal of transplantation, 2013-02, Vol.13 (s3), p.55-66 |
| issn | 1600-6135 1600-6143 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1323807217 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Antiviral Agents - therapeutic use Chickenpox - complications Chickenpox - etiology Child Drug Resistance, Viral Ganglia - metabolism Herpes simplex Herpes Simplex - complications Herpes Simplex - etiology Herpes simplex virus Herpesviridae Herpesvirus 3, Human - metabolism Humans Organ Transplantation - adverse effects prevention Risk Factors Simplexvirus - metabolism transplantation treatment Treatment Outcome Vaccines varicella Varicella-zoster virus |
| title | Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in Solid Organ Transplant Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T23%3A54%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Varicella%20Zoster%20Virus%20(VZV)%20and%20Herpes%20Simplex%20Virus%20(HSV)%20in%20Solid%20Organ%20Transplant%20Patients&rft.jtitle=American%20journal%20of%20transplantation&rft.au=Zuckerman,%20R.%20A.&rft.date=2013-02&rft.volume=13&rft.issue=s3&rft.spage=55&rft.epage=66&rft.pages=55-66&rft.issn=1600-6135&rft.eissn=1600-6143&rft_id=info:doi/10.1111/ajt.12003&rft_dat=%3Cproquest_cross%3E2873744821%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1272346363&rft_id=info:pmid/23347214&rfr_iscdi=true |